Use of recombinant coagulation factor IX in the surgical treatment of a patient with severe hemophilia B

DOI: https://doi.org/10.29296/25877305-2019-05-12
Download full text PDF
Issue: 
5
Year: 
2019

Professor I. Davydkin, MD(1); I. Kurtov, Candidate of Medical Sciences(1); S. Ardatov, Candidate of Medical Sciences(1); Yu. Kim(1), A. Shuster, Candidate of Biological Sciences(2); Professor D. Kudlay, MD(2); A. Borozinets, Candidate of Medical Sciences(2) 1-Samara State Medical University 2-AO «GENERIUM», Moscow

Hemophilia B is one of the inherited coagulopathies associated with coagulation factor IX deficiency. If there is a need for surgical treatment, patients receive replacement therapy with drugs containing IX coagulation factor. In the Russian Federation, there is a state program «Development of the Pharmaceutical and Medical Industry» for 2013–2020, aimed at increasing the production and availability of Russian vital and essential medicines, including those for the treatment of hemophilia A and B. A clinical example of the effective use of recombinant coagulation factor IX (Innonafactor, nonacog alfa, AO «GENERIUM») is described for the first time in the surgical treatment of closed right humeral mid-shaft fracture with displaced fragments in a patient with severe hemophilia B.

Keywords: 
hematology
hemophilia B
recombinant coagulation factor IX
closed right humeral mid-shaft fracture
osteosynthesis of the right humerus



It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Colvin B., Astermark J., Fischer K. et al. European principles of. Haemophilia care // Haemophilia. – 2008; 14: 361–74.
  2. De Moerloose P., Fischer K., Lambert T. et al. Recommendations for assessment, monitoring and follow-up of patients with haemophilia // Haemophilia. – 2012; 18: 319–25.
  3. Srivastava A., Brewer A., Mauser-Bunschoten E. et al. Guidelines for the management of hemophilia (WFH) // Haemophilia. – 2013; 19: e1–e47.
  4. Zozulja N.I., Kumskova M.A. Protokol diagnostiki i lechenija gemofilii. V kn.: Algoritmy diagnostiki i protokoly lechenija zabolevanij sistemy krovi. Abramova A.V., Abdullaev A.O., Azimova M.H., Al'-Radi L.S., Biderman B.V. i dr. / M., 2018; s. 333–57 [Zozulja N.I., Kumskova M.A. Protokol diagnostiki i lechenija gemofilii. V kn.: Algoritmy diagnostiki i protokoly lechenija zabolevanij sistemy krovi. Abramova A.V., Abdullaev A.O., Azimova M.H., Al’-Radi L.S., Biderman B.V. et al. / M., 2018; p. 333–57 (in Russ.)].
  5. Osnovy klinicheskoj gemostaziologii i gemoreologii: monografija. Pod red. I.L. Davydkina, A.P. Momota, N.I. Zozuli, E.V. Rojtmana / Samara: OOO IPK «Samarskaja Gubernija», 2017 [Osnovy klinicheskoj gemostaziologii i gemoreologii: monografija. Pod red. I.L. Davydkina, A.P. Momota, N.I. Zozuli, E.V. Rojtmana / Samara: OOO IPK «Samarskaja Gubernija», 2017 (in Russ.)].
  6. Protokol vedenija bol'nyh «Gemofilija». Problemy standartizatsii v zdravoohranenii. 2006; 18–74 s. [Protokol vedenija bol’nyh «Gemofilija». Problemy standartizacii v zdravoohranenii. 2006; 18–74 p. (in Russ.)].
  7. Gosudarstvennaja programma «Razvitie farmatsevticheskoj i meditsinskoj promyshlennosti» na 2013–2020 gody [Elektronnyj resurs]: Osnovnye dannye po gosudarstvennoj programme «Razvitie farmatsevticheskoj i meditsinskoj promyshlennosti» na 2013–2020 gody / M.: Minpromtorg Rossii, 2014. Rezhim dostupa: http://minpromtorg.gov.ru/common/upload/files/docs/MinProm_02.06.14.pdf, svobodnyj. – Zagl. s ekrana. [Gosudarstvennaja programma «Razvitie farmacevticheskoj i medicinskoj promyshlennosti» na 2013–2020 gody [Jelektronnyj resurs]: Osnovnye dannye po gosudarstvennoj programme «Razvitie farmacevticheskoj i medicinskoj promyshlennosti» na 2013–2020 gody / M.: Minpromtorg Rossii, 2014. Rezhim dostupa: http://minpromtorg.gov.ru/common/upload/files/docs/MinProm_02.06.14.pdf, svobodnyj. – Zagl. s jekrana (in Russ.)].
  8. Kudlaj D.A. Razrabotka i primenenie otechestvennyh rekombinantnyh preparatov faktorov svertyvanija krovi VII, VIII, IX u detej s gemofiliej A i B // Pediatrija. Zhurnal im. G.N. Speranskogo. – 2019; 98 (1): 9–17 [Kudlaj D.A. Development and use of Russian recombinant blood coagulation factor VII, VIII, IX drugs in children with hemophilia A and B // Pediatria. Journal named after G.N. Speransky. – 2019; 98 (1): 9–17 (in Russ.)].
  9. Zorenko V.Ju., Mishin G.V., Severova T.V. i dr. Farmakokineticheskie svojstva, bezopasnost' i perenosimost' preparata Oktofaktor (rezul'taty I fazy klinicheskogo issledovanija u bol'nyh gemofiliej A) // Vopr. gematol. onkol. i immunopatol. v pediat. – 2013; 12 (2): 30–7 [Zorenko V.Yu., Mishin G.V., Severova T.V. et al. Pharmacokinetics, safety, and tolerability of Octofactor in patients with hemophilia A: Results of phase I clinical study // Vopr. gematol. onkol. i immunopatol. v pediat. – 2013; 12 (2): 30–7 (in Russ.)]
  10. Davydkin I.L., Andreeva T.A., Zorenko V.Ju. i dr. Effektivnost' i bezopasnost' preparata Oktofaktor pri profilakticheskom lechenii bol'nyh s tjazheloj i srednetjazheloj formoj gemofilii A (rezul'taty 1-j chasti klinicheskogo issledovanija II–III fazy) // Vopr. gematol. onkol. i immunopatol. v pediat. – 2013; 12 (3): 29–37 [Davydkin I.L., Andreeva T.A., Zorenko V.Yu., et al. Efficiency and safety of Octofactor in the treatment of patients with severe and moderate hemophilia A: Results of part 1 of phase II–III clinical trial // Vopr. gematol. onkol. i immunopatol. v pediat. – 2013; 12 (3): 29–37 (in Russ.)].
  11. Andreeva T.A., Zorenko V.Ju., Davydkin I.L. i dr. Effektivnost' i bezopasnost' preparata Oktofaktor v lechenii bol'nyh s tjazheloj i srednetjazheloj formoj gemofilii A (rezul'taty 2-j chasti klinicheskogo issledovanija II i III fazy) // Vopr. gematol. onkol. i immunopatol. v pediat. – 2013; 12 (4): 31–7 [Andreeva T.A., Zorenko V.Yu., Davydkin I.L. et al. Efficiency and safety of Octofactor in the treatment of patients with severe and moderate hemophilia A: Results of part 2 of phase II–III clinical trial // Vopr. gematol. onkol. i immunopatol. v pediat. – 2013; 12 (4): 31–7 (in Russ.)].
  12. Zorenko V.Ju., Mishin G.V., Severova T.V. i dr. Farmakokineticheskie svojstva, bezopasnost' i perenosimost' preparata Innonafaktor (rezul'taty I fazy klinicheskogo issledovanija u bol'nyh s tjazheloj i srednetjazheloj formoj gemofilii B) // Vopr. gematol. onkol. i immunopatol. v pediat. – 2014; 13 (4): 39–49 [Zorenko V.Yu., Mishin G.V., Severova T.V. et al. Pharmacokinetics, safety, and tolerability of Innonafactor: Results of phase I clinical study in patients with severe and moderate hemophilia B // Vopr. gematol. onkol. i immunopatol. v pediat. – 2014; 13 (4): 39–49 (in Russ.)].
  13. Andreeva T.A., Zorenko V.Ju., Davydkin I.L. i dr. Effektivnost' i bezopasnost' preparata Innonafaktor pri profilakticheskom lechenii bol'nyh s tjazheloj i srednetjazheloj formoj gemofilii V (rezul'taty 1-j chasti klinicheskogo issledovanija II–III fazy) // Vopr. gematol. onkol. i immunopatol. v pediat. – 2015; 14 (1): 65–75 [Andreeva T.A., Zorenko V.Yu., Davydkin I.L. et al. Efficiency and safety of Innonafactor in prevention of bleeding episodes in patients with severe and moderate hemophilia B: Results of part 1 of phase II–III clinical trial // Vopr. gematol. onkol. i immunopatol. v pediat. – 2015; 14 (1): 65–75 (in Russ.)].
  14. Davydkin I.L., Zorenko V.Ju., Andreeva T.A. i dr. Effektivnost' i bezopasnost' preparata Innonafaktor v lechenii bol'nyh s tjazheloj i srednetjazheloj formoj gemofilii B (rezul'taty 2-j chasti klinicheskogo issledovanija II–III fazy) // Vopr. gematol. onkol. i immunopatol. v pediat. – 2015; 14 (2): 50–8 [Davydkin I.L., Zorenko V.Yu., Andreeva T.A. et al. Efficiency and safety of Innonafactor in prevention of bleeding episodes in patients with severe and moderate hemophilia B: Results of part 2 of phase II–III clinical trial // Vopr. gematol. onkol. i immunopatol. v pediat. – 2015; 14 (2): 50–8 (in Russ.)].
  15. Andreeva T.A., Davydkin I.L., Mamaev A.N. i dr. Rezul'taty mnogotsentrovogo, prospektivnogo, otkrytogo, nekontroliruemogo issledovanija effektivnosti i bezopasnosti preparata Innonafaktor u patsientov v vozraste 12 let i starshe s tjazheloj i srednetjazheloj gemofiliej V // Rossijskij zhurnal detskoj gematologii i onkologii. – 2017; 4 (4): 20–32 [Andreeva T.A., Davydkin I.L., Mamaev A.N., et al. Results of a multicenter, prospective, open, uncontrolled study of the efficacy and safety of the drug Innonafactor in patients aged 12 years and older with severe and moderate hemophilia B // Rossijskij zhurnal detskoj gematologii i onkologii. – 2017; 4 (4): 20–32 (in Russ.)].
  16. Davydkin I., Andreeva T., Zorenko V. et al. Safety and efficiency of new nonacog alfa drug in the treatment of bleeding episodes in patients with severe and moderate hemophilia B // Blood. – 2015; 126 (23): 4690.
  17. Pravila provedenija issledovanij biologicheskih lekarstvennyh sredstv Evrazijskogo ekonomicheskogo sojuza. 2016; 714 s. Rezhim dostupa: https://docs.eaeunion.org/docs/ru-ru/01411954/cncd_21112016_89, svobodnyj. – Zagl. s ekrana. [Pravila provedenija issledovanij biologicheskih lekarstvennyh sredstv Evrazijskogo jekonomicheskogo sojuza. 2016; 714 s. Rezhim dostupa: https://docs.eaeunion.org/docs/ru-ru/01411954/cncd_21112016_89, svobodnyj. – Zagl. s jekrana (in Russ.)].
  18. Ivanov R., Sekareva G., Kravtsova O. i dr. Pravila provedenija issledovanij bioanalogovyh lekarstvennyh sredstv (bioanalogov) // Farmakokinetika i farmakodinamika. – 2014; 1: 21–36 [Ivanov R., Sekarjova G., Kravcova O. et al. Ivanov R., Sekarnva G., Kravtsova O. et al. Guidelines of research biosimilar drugs // Farmakokinetika i farmakodinamika. – 2014; 1: 21–36 (in Russ.)].
  19. Mamaev A.N., Kudlaj D.A. Vizualizatsija dannyh v prezentatsijah, otchetah i issledovanijah / M.: Prakticheskaja meditsina, 2011; 39 s. [Mamaev A.N., Kudlaj D.A. Vizualizacija dannyh v prezentacijah, otchetah i issledovanijah / M.: Prakticheskaja medicina, 2011; 39 p. (in Russ.)].
  20. Andreev Ju.N. Mnogolikaja gemofilija / M.: N'judiamed, 2006; 232 c. [Andreev Yu.N. Mnogolikaja gemofilija / M.: N’judiamed, 2006; 232 p. (in Russ.)].